Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Eligibility criteria
Qualifiers
Male and female subjects with multiple myeloma or plasmacytoma
Strictly complete remission (sCR) is a treatment goal
Expected survival > 12 weeks
After prior auto-SCT is eligible regardless of other prior therapies
Disqualifiers
Pregnant or lactating women
Uncontrolled active infection
Active HIV, hepatitis B or hepatitis C infection
Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
Trial design
Treatments tested in this trial
- CAR-T cells
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov